{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:09:06Z","timestamp":1791806946149,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.canlet.2023.216568","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:30:32Z","timestamp":1701865832000},"page":"216568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway"],"prefix":"10.1016","volume":"582","author":[{"given":"Limin","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuSen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216568_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2023.216568_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2023.216568_bib3","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2022-327133","article-title":"Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients","volume":"72","author":"Tan","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2023.216568_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2023.216568_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.30593","article-title":"Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer","volume":"70","author":"Wu","year":"2019","journal-title":"Hepatology (Baltimore, Md"},{"key":"10.1016\/j.canlet.2023.216568_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.09.015","article-title":"Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8(+) T cells in liver cancer","volume":"495","author":"Qian","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216568_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.gastro.2013.01.002","article-title":"Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma","volume":"144","author":"Hernandez-Gea","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2023.216568_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.immuni.2016.02.024","article-title":"Tissue-resident macrophage ontogeny and homeostasis","volume":"44","author":"Ginhoux","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216568_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cellimm.2018.02.008","article-title":"Myeloid cell heterogeneity in cancer: not a single cell alike","volume":"330","author":"Kiss","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2023.216568_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The multifaceted role of perivascular macrophages in tumors","volume":"30","author":"Lewis","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216568_bib11","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse functions of macrophages in different tumor microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216568_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1286-4579(00)00296-3","article-title":"The macrophage receptor MARCO","volume":"2","author":"Kraal","year":"2000","journal-title":"Microb. Infect."},{"key":"10.1016\/j.canlet.2023.216568_bib13","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2002-12-3651","article-title":"The scavenger receptor MARCO mediates cytoskeleton rearrangements in dendritic cells and microglia","volume":"102","author":"Granucci","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216568_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/toxsci\/kfp011","article-title":"Critical role of MARCO in crystalline silica-induced pulmonary inflammation","volume":"108","author":"Thakur","year":"2009","journal-title":"Toxicol. Sci. : an official journal of the Society of Toxicology"},{"key":"10.1016\/j.canlet.2023.216568_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.toxlet.2018.10.031","article-title":"Inhibition of MARCO ameliorates silica-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition","volume":"301","author":"Yang","year":"2019","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.canlet.2023.216568_bib16","doi-asserted-by":"crossref","first-page":"30406","DOI":"10.1074\/jbc.M414686200","article-title":"Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid","volume":"280","author":"Alarc\u00f3n","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2023.216568_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s000180050191","article-title":"Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system","volume":"54","author":"Yamada","year":"1998","journal-title":"Cell. Mol. Life Sci. : CMLS"},{"key":"10.1016\/j.canlet.2023.216568_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207201119","article-title":"Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression","volume":"119","author":"Yang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216568_bib19","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210564","article-title":"Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer","volume":"219","author":"Masetti","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2023.216568_bib20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","article-title":"Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function","volume":"81","author":"La Fleur","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216568_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.771488","article-title":"The scavenger receptor MARCO expressed by tumor-associated macrophages are highly associated with poor pancreatic cancer prognosis","volume":"11","author":"Shi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216568_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(99)00350-7","article-title":"Pharmacological characterization of recombinant human and rat P2X receptor subtypes","volume":"376","author":"Bianchi","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216568_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 purinergic signalling in the tumour microenvironment","volume":"18","author":"Di Virgilio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216568_bib24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8(+) T cell subsets in antitumor immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2023.216568_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/2326-6066.CIR-15-0110","article-title":"Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC","volume":"4","author":"Gabrielson","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2023.216568_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216568_bib27","first-page":"36","article-title":"Regulation of type I interferon responses, Nature reviews","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2023.216568_bib28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216568_bib29","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.7150\/thno.37574","article-title":"STING activation in cancer immunotherapy","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2023.216568_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2023.216568_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and clearance of apoptotic cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216568_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.immuni.2020.01.014","article-title":"Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP","volume":"52","author":"Zhou","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216568_bib33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ccell.2018.03.027","article-title":"Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells","volume":"33","author":"Ahn","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216568_bib34","series-title":"BAK\/BAX Macropores Facilitate Mitochondrial Herniation and mtDNA Efflux during Apoptosis","first-page":"359","author":"McArthur","year":"2018"},{"key":"10.1016\/j.canlet.2023.216568_bib35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.cell.2014.11.036","article-title":"Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production","volume":"159","author":"White","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216568_bib36","first-page":"345","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors, Nature reviews","volume":"18","author":"Doroshow","year":"2021","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216568_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216568_bib38","doi-asserted-by":"crossref","first-page":"32005","DOI":"10.1073\/pnas.2015343117","article-title":"Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells","volume":"117","author":"Eisinger","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216568_bib39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216568_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights, Nature reviews","volume":"18","author":"Borden","year":"2019","journal-title":"Drug discovery"},{"key":"10.1016\/j.canlet.2023.216568_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy, Cellular and molecular life sciences","volume":"79","author":"Yu","year":"2022","journal-title":"CMLS"},{"key":"10.1016\/j.canlet.2023.216568_bib42","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216568_bib43","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216568_bib44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.celrep.2019.09.065","article-title":"Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity","volume":"29","author":"Schadt","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2023.216568_bib45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523005190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523005190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:15:27Z","timestamp":1759594527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523005190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":45,"alternative-id":["S0304383523005190"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216568","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216568"}}